文献速递自身炎症与 IgG4 相关病其他结缔组织病

新发显性负性PSMB8突变因蛋白酶体组装停滞导致严重CANDLE/PRAAS

A de novo dominant-negative PSMB8 mutation causes severe CANDLE/PRAAS due to arrested proteasome biogenesis.
PubMed 文献 · Ann Rheum Dis · 2025-11-17

该研究评估携带新发显性负性PSMB8 p.G209R变异(编码20S免疫蛋白酶体突变β5i亚基)患者的病理机制与治疗反应。变异通过空间位阻阻碍β5i前肽加工及最终20S蛋白酶体形成,导致蛋白聚集、线粒体代谢受损,患者T细胞IFN-I特征可被PKR/GCN2或JAK抑制所降低。临床表现包括早发系统性炎症、脂膜炎、血细胞减少、感染及门窦血管性肝病(PSVD)。

要点

  • DN-PSMB8 p.G209R变异导致20S蛋白酶体成熟停滞,拓宽PRAAS临床与机制谱。
  • 患者表现为早发系统性炎症、脂膜炎、血细胞减少、感染及PSVD。
  • PKR和GCN2是适应不良IFN-I反应的关键介质及潜在治疗靶点。

核心结论

  • DN-PSMB8 p.G209R变异通过引起20S蛋白酶体成熟停滞拓宽PRAAS临床与机制谱,并揭示线粒体功能障碍与整合应激反应(ISR)的汇聚。
  • 研究提示血细胞减少与包括肝脏PSVD在内的血管病理模式相关。
  • PKR和GCN2被确定为适应不良IFN-I反应的关键介质及潜在治疗靶点。

研究设计与样本

  • 评估携带DN-PSMB8 p.G209R变异(编码20S免疫蛋白酶体突变β5i亚基)的患者。
  • 检测干扰素生物标志物、蛋白酶体活性、结构建模及蛋白毒性应激反应。
  • 对患者T细胞进行整合转录组与蛋白质组分析,以表征免疫失调、蛋白毒性应激反应、线粒体功能及I型干扰素(IFN-I)相关应激信号。

主要发现

  • DN-PRAAS患者表现为早发系统性炎症、脂膜炎、血细胞减少、感染及门窦血管性肝病(PSVD),部分对Janus激酶抑制和/或干扰素-α/β受体阻断(anifrolumab)有反应。
  • PSMB8 p.G209R变异引起空间位阻,损害β5i前肽加工及最终20S蛋白酶体形成,导致细胞内蛋白聚集、线粒体代谢受损及中性脂质加工改变。
  • 患者T细胞的IFN-I特征可被阻断两种整合应激反应(ISR)调节激酶——蛋白激酶R(PKR)和一般性调控阻遏蛋白2(GCN2)——以及Janus激酶信号所降低。

关键数值与推荐

  • DN-PSMB8 p.G209R变异编码20S免疫蛋白酶体突变β5i亚基。
  • 患者T细胞IFN-I特征在阻断PKR和GCN2或抑制Janus激酶信号后降低。

临床怎么用

  • DN-PRAAS患者可表现为早发系统性炎症、脂膜炎、血细胞减少、感染及PSVD。
  • Janus激酶抑制和/或干扰素-α/β受体阻断(anifrolumab)可使部分患者获得部分反应。
  • PKR和GCN2被确定为适应不良IFN-I反应的潜在治疗靶点。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Proteasome-associated autoinflammatory syndromes (PRAAS) include a group of autoinflammatory interferonopathies caused by 20S proteasome dysfunction. We characterised pathomechanisms and treatment responses of patients with a de novo, dominant-negative (DN)-proteasome subunit beta type-8 (PSMB8) variant. METHODS: Patients with the DN-PSMB8 p.G209R variant encoding a mutant β5i subunit of the 20S immunoproteasome were evaluated. Interferon biomarkers, proteasome activity, structural modelling, and proteotoxic stress responses were assessed. Patients' T cells underwent integrated transcriptomic and proteomic profiling to characterise immune dysregulation, proteotoxic stress responses, mitochondrial function, and type I interferon (IFN-I) associated stress signalling. RESULTS: Patients with DN-PRAAS presented with early-onset systemic inflammation, panniculitis, cytopenias, infections, and porto-sinusoidal vascular liver disease (PSVD), indicating broader immune dysfunction that partially responds to Janus kinase inhibition and/or interferon-α/β receptor blockade (anifrolumab). Mechanistically, the PSMB8 p.G209R variant caused steric hindrance that impaired β5i propeptide processing and final 20S proteasome formation, resulting in intracellular protein aggregation, impaired mitochondrial metabolism, and altered neutral lipid processing. The IFN-I signature of patients' T cells was reduced by blockade of 2 integrated stress response (ISR)-regulating kinases, protein kinase R (PKR) and general control nonderepressible 2 (GCN2), and by Janus kinase signalling. CONCLUSIONS: The DN-PSMB8 p.G209R variant broadens the clinical and mechanistic PRAAS spectrum by causing 20S proteasome maturation arrest and uncovering a convergence between mitochondrial dysfunction and the ISR. Our findings implicate cytopenia in a pattern of vascular pathology, including PSVD of the liver. We further identify PKR and GCN2 as key mediators of maladaptive IFN-I responses and potential therapeutic targets.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Wolfgramm S, Alehashemi S, Wendlandt M, et al. A de novo dominant-negative PSMB8 mutation causes severe CANDLE/PRAAS due to arrested proteasome biogenesis. Ann Rheum Dis. 2025. PMID: 41253591. doi:10.1016/j.ard.2025.10.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。